Skip to content
  • BiotechReality JobFinder
  • Market Analysis
  • Publish on BiotechReality
  • linkedin
  • facebook
  • instagram
  • twitter
BiotechReality Home
BiotechReality – Information Intelligence System for Biopharma
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
Popular
#FDA #Eli Lilly and Company #Johnson&Johnson #Clinical Data #FDA Approval #Cancer #Novo Nordisk #Phase 3 Trials

Tag: Glucose-Ketone Sensor

Technology Diabetes Healthcare & Pharmaceuticals News

Abbott Libre Duo 10 Day Wins FDA Authorization as World’s First Dual Glucose-Ketone Sensor

  • By Regulatory Intelligence Desk
  • 26 August 2026
Abbott News

Abbott Libre Duo 10 Day has received FDA authorization as the world’s first dual glucose-ketone biowearable, designed to alert people with diabetes to rising DKA risk while tracking glucose in real time.

Tagged Abbott, Abbott Libre, FDA, Glucose-Ketone Sensor
Advertisement

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Autoimmune Diseases
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biologics
  • Biosimilars
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • CDMO
  • Cell Biology
  • Clinical Data
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • CRDMO
  • CRO
  • Cybersecurity
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Legal and Patent Affairs
  • Life Sciences
  • Machine Learning
  • Manufacturing
  • Medical Devices
  • Mental Health
  • Merger & Acquisitions
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Rare Diseases
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs

Discover More

Roche Tecentriq Colon Cancer Milestone: FDA Approves Tecentriq and Tecentriq Hybreza With Chemotherapy for Stage III dMMR Disease
Regulatory Approval Cancer Clinical Trials Healthcare & Pharmaceuticals News

Roche Tecentriq Colon Cancer Milestone: FDA Approves Tecentriq and Tecentriq Hybreza With Chemotherapy for Stage III dMMR Disease

9 October 20269 October 2026
Regulatory Intelligence Desk
Pfizer TUKYSA FDA Approval: Chemotherapy-Free Front-Line Maintenance Now Available for HER2+ Metastatic Breast Cancer
Regulatory Approval Cancer Clinical Trials Healthcare & Pharmaceuticals News

Pfizer TUKYSA FDA Approval: Chemotherapy-Free Front-Line Maintenance Now Available for HER2+ Metastatic Breast Cancer

9 October 20269 October 2026
Regulatory Intelligence Desk
Novartis Rhapsido FDA Approval: Remibrutinib Becomes First Treatment for Symptomatic Dermographism
Regulatory Approval Healthcare & Pharmaceuticals News

Novartis Rhapsido FDA Approval: Remibrutinib Becomes First Treatment for Symptomatic Dermographism

8 October 20268 October 2026
Regulatory Intelligence Desk
Lilly Indiana Manufacturing Investment of $4.5 Billion, Opens Dedicated Genetic Medicine Facility
Business Healthcare & Pharmaceuticals News

Lilly Indiana Manufacturing Investment of $4.5 Billion, Opens Dedicated Genetic Medicine Facility

7 October 20267 October 2026
BiotechReality Business Intelligence Desk
Charles River Rapid Cell Banking Programs Cut Production Timelines by 40% With NGS Characterization
Business Healthcare & Pharmaceuticals News

Charles River Rapid Cell Banking Programs Cut Production Timelines by 40% With NGS Characterization

7 October 20267 October 2026
BiotechReality Business Intelligence Desk
ViiV Healthcare Cabenuva Meets Primary Endpoint in Phase IIIb CROWN Study of People With HIV Viremia
Clinical Data Clinical Trials Healthcare & Pharmaceuticals News

ViiV Healthcare Cabenuva Meets Primary Endpoint in Phase IIIb CROWN Study of People With HIV Viremia

6 October 20266 October 2026
Clinical Trials & Data Desk
Advertisement
BiotechReality JobFinder

  • Commercial Product Manager – Centrifuge – ThermoFisher, Singapore & Malaysia
    7 October 2026
  • Regulatory Affairs Specialist – Lonza, Hyderabad
    4 October 2026
  • Component Engineer – Cytiva, Bangalore
    29 September 2026
  • Manufacturing Manager – Novartis, Japan
    28 September 2026
  • Principal Application Specialist FMT APAC – Sartorius, Singapore
    27 September 2026

BiotechReality Shots Weekly Newsletter

Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2026
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
  • linkedin
  • facebook
  • instagram
  • twitter